In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca R&D: Balancing Caution & Ambition

Executive Summary

Late-stage setbacks recently forced AstraZeneca to re-think its risk management in the development and regulatory stages, but the process has already started within discovery research. Head of discovery Jan Lundberg told the audience of Windhover's 13th audio-conference in December 2004 how the Big Pharma is adapting to a tougher market environment and attempting to balance caution with ambition.
Advertisement

Related Content

Know Thy R&D Enemy: The Key to Fighting Attrition
Know Thy R&D Enemy: The Key to Fighting Attrition
CAT Gains from AZ Antibody Drive
CAT Gains from AZ Antibody Drive
Big Pharma's Large Molecule Challenge
Big Pharma's Large Molecule Challenge
AstraZeneca's Iressa Problem
AstraZeneca's Iressa Problem
AstraZeneca's Nuanced View of Drug Development
AstraZeneca's Nuanced View of Drug Development

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel